With effective PDX models of primary and recurrent osteosarcoma patients, we provided further clinical-relevant evidence for PLK1 targeted therapies and demonstrated the high specificity of Volasertib as a promising clinical candidate. The gene discussed is PLK1; the disease is osteosarcoma.